Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-08-2016 | Review – Cancer Research

Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?

Authors: Maria Schubert, Kerstin Junker, Joana Heinzelmann

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2016

Abstract

Purpose

Defining reliable biomarkers is still a challenge in patients with urological tumors. Because miRNAs regulate diverse important cellular processes, these noncoding RNAs are putative molecular candidates. This review intends to give a critical overview about the current state of miRNAs as biomarkers in urological cancers with respect to prognostic stratification as well as for individual treatment selection.

Methods

A comprehensive review of the published literature was conducted focusing at the clinical relevance of miRNAs in tissues and body fluids of prostate, bladder and kidney cancer. Using electronic database, 91 articles, published between 2009 and 2015, were selected and discussed regarding the robustness of miRNAs as valid biomarkers.

Results

A number of miRNAs have been identified with prognostic and predictive relevance in different urologic tumor types. However, the inconsistency of the published results and the lack of multivariate testing in independent cohorts do not allow an introduction into clinical decision making at present.

Conclusion

miRNA-based biomarkers are a promising tool for future personalized risk stratification and response prediction in urological cancers.

Adam L, Zhong M et al (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15:5060–5072. doi:10.1158/1078-0432.CCR-08-2245 PubMedCrossRef

Adam L, Wszolek MF et al (2013) Plasma microRNA profiles for bladder cancer detection. Urol Oncol 31:1701–1708. doi:10.1016/j.urolonc.2012.06.010 PubMedCrossRef

Ambs S, Prueitt RL et al (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68:6162–6170. doi:10.1158/0008-5472.CAN-08-0144 PubMedPubMedCentralCrossRef

Andrew AS, Marsit CJ et al (2015) Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence. Int J Cancer. doi:10.1002/ijc.29413 PubMed

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297. doi:10.1016/S0092-8674(04)00045-5 PubMedCrossRef

Berkers J, Govaere O et al (2012) A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance. J Urol 189:1930–1938. doi:10.1016/j.juro.2012.11.133 PubMedCrossRef

Brase JC, Johannes M et al (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128:608–616. doi:10.1002/ijc.25376 PubMedCrossRef

Bray F, Sankila R, Ferlay J, Parkin DM (2002) Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38:99–166PubMedCrossRef

Bryant RJ, Pawlowski T et al (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106:768–774. doi:10.1038/bjc.2011.595 PubMedPubMedCentralCrossRef

Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L (2010) Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 78:838–848. doi:10.1038/ki.2010.278 PubMedCrossRef

Carden CP, Sarker D et al (2010) Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov Today 15:88–97. doi:10.1016/j.drudis.2009.11.006 PubMedCrossRef

Catto JW, Miah S et al (2009) Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69:8472–8481. doi:10.1158/0008-5472.CAN-09-0744 PubMedPubMedCentralCrossRef

Catto JW, Alcaraz A et al (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59:671–681. doi:10.1016/j.eururo.2011.01.044 PubMedCrossRef

Cho WC (2010) MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 42:1273–1281. doi:10.1016/j.biocel.2009.12.014 PubMedCrossRef

Choi W, Porten S et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152–165. doi:10.1016/j.ccr.2014.01.009 PubMedPubMedCentralCrossRef

Chow TF, Youssef YM et al (2010) Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 43:150–158. doi:10.1016/j.clinbiochem.2009.07.020 PubMedCrossRef

Cummings J, Raynaud F, Jones L, Sugar R, Dive C (2010) Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Br J Cancer 103:1313–1317. doi:10.1038/sj.bjc.6605910 PubMedPubMedCentralCrossRef

Damrauer JS, Hoadley KA et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA 111:3110–3115. doi:10.1073/pnas.1318376111 PubMedPubMedCentralCrossRef

Dip N, Reis ST et al (2012) Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile. J Urol 188:1951–1956. doi:10.1016/j.juro.2012.07.004 PubMedCrossRef

Drayton RM, Dudziec E et al (2014) Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res 20:1990–2000. doi:10.1158/1078-0432.CCR-13-2805 PubMedPubMedCentralCrossRef

Dyrskjot L, Ostenfeld MS et al (2009) Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69:4851–4860. doi:10.1158/0008-5472.CAN-08-4043 PubMedCrossRef

Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon

Faragalla H, Youssef YM et al (2012) The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn 14:385–392. doi:10.1016/j.jmoldx.2012.02.003 PubMedCrossRef

Ferlay J, Autier P et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592. doi:10.1093/annonc/mdl498 PubMedCrossRef

Ferlay J, Steliarova-Foucher E et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403. doi:10.1016/j.ejca.2012.12.027 PubMedCrossRef

Fridman E, Dotan Z et al (2010) Accurate molecular classification of renal tumors using microRNA expression. J Mol Diagn 12:687–696. doi:10.2353/jmoldx.2010.090187 PubMedPubMedCentralCrossRef

Fritz HK, Lindgren D, Ljungberg B, Axelson H, Dahlback B (2014) The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. Eur J Cancer 50:1758–1765PubMedCrossRef

Gamez-Pozo A, Anton-Aparicio LM et al (2012) MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 14:1144–1152PubMedPubMedCentralCrossRef

Gonzales JC, Fink LM et al (2011) Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 9:39–45. doi:10.1016/j.clgc.2011.05.008 PubMedCrossRef

Gowrishankar B, Ibragimova I et al (2014) MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 15:329–341. doi:10.4161/cbt.27314 PubMedCrossRef

Hagman Z, Haflidadottir BS et al (2013) miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer 108:1668–1676. doi:10.1038/bjc.2013.131 PubMedPubMedCentralCrossRef

Hart M, Nolte E et al (2014) Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. Mol Cancer Res 12:250–263. doi:10.1158/1541-7786.MCR-13-0230 PubMedCrossRef

Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20:460–469. doi:10.1016/j.molmed.2014.06.005 PubMedCrossRef

Heinzelmann J, Henning B et al (2011) Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 29:367–373. doi:10.1007/s00345-010-0633-4 PubMedCrossRef

Heinzelmann J, Unrein A et al (2014) MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases. Ann Surg Oncol 21:1046–1054PubMedCrossRef

Hughes C, Murphy A et al (2006) Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma. J Clin Pathol 59:721–724. doi:10.1136/jcp.2005.029975 PubMedPubMedCentralCrossRef

Jia AY, Castillo-Martin M et al (2013) A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. Am J Pathol 182:1171–1179. doi:10.1016/j.ajpath.2013.01.006 PubMedPubMedCentralCrossRef

Jiang X, Du L et al (2015) Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer 136:854–862. doi:10.1002/ijc.29041 PubMedCrossRef

Kalogirou C, Spahn M et al (2013) MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer. Int J Mol Sci 14:21414–21434. doi:10.3390/ijms141121414 PubMedPubMedCentralCrossRef

Khella HW, Scorilas A et al (2015) Low expression of miR-126 is a prognostic marker for metastatic clear cell renal cell carcinoma. Am J Pathol 185:693–703PubMedCrossRef

Kim SM, Kang HW et al (2013) Cell-free microRNA-214 from urine as a biomarker for non-muscle-invasive bladder cancer. Korean J Urol 54:791–796PubMedPubMedCentralCrossRef

Kneitz B, Krebs M et al (2014) Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res 74:2591–2603. doi:10.1158/0008-5472.CAN-13-1606 PubMedCrossRef

Knowles MA (2008) Molecular pathogenesis of bladder cancer. Int J Clin Oncol 13:287–297. doi:10.1007/s10147-008-0812-0 PubMedCrossRef

Kobayashi N, Uemura H et al (2012) Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget 3:1455–1471PubMedPubMedCentralCrossRef

Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M (2010) MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70:1501–1512. doi:10.1002/pros.21185 PubMedCrossRef

Kozinn SI, Harty NJ et al (2013) MicroRNA profile to predict gemcitabine resistance in bladder carcinoma cell lines. Genes Cancer 4:61–69. doi:10.1177/1947601913484495 PubMedPubMedCentralCrossRef

Kozomara A, Griffiths-Jones S (2011) miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39:D152–D157. doi:10.1093/nar/gkq1027 PubMedCrossRef

Larne O, Martens-Uzunova E et al (2013) miQ—a novel microRNA based diagnostic and prognostic tool for prostate cancer. Int J Cancer 132:2867–2875. doi:10.1002/ijc.27973 PubMedCrossRef

Lee H, Jun SY et al (2014) Expression of miRNAs and ZEB1 and ZEB2 correlates with histopathological grade in papillary urothelial tumors of the urinary bladder. Virchows Arch 464:213–220. doi:10.1007/s00428-013-1518-x PubMedCrossRef

Li T, Li RS et al (2012) miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol 187:1466–1472. doi:10.1016/j.juro.2011.11.082 PubMedCrossRef

Lichner Z, Fendler A et al (2013) MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin Chem 59:1595–1603. doi:10.1373/clinchem.2013.205450 PubMedCrossRef

Lin HM, Castillo L et al (2014) Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer 110:2462–2471. doi:10.1038/bjc.2014.181 PubMedPubMedCentralCrossRef

Ljungberg B, Campbell SC et al (2011) The epidemiology of renal cell carcinoma. Eur Urol 60:615–621. doi:10.1016/j.eururo.2011.06.049 PubMedCrossRef

Lodes MJ, Caraballo M et al (2009) Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 4:e6229. doi:10.1371/journal.pone.0006229 PubMedPubMedCentralCrossRef

Marchio C, Dowsett M, Reis-Filho JS (2011) Revisiting the technical validation of tumour biomarker assays: how to open a Pandora’s box. BMC Med 9:41. doi:10.1186/1741-7015-9-41 PubMedPubMedCentralCrossRef

Marin-Aguilera M, Codony-Servat J et al (2012) Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther 11:329–339. doi:10.1158/1535-7163.MCT-11-0289 PubMedCrossRef

Mavridis K, Stravodimos K, Scorilas A (2013) Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem 59:261–269. doi:10.1373/clinchem.2012.191502 PubMedCrossRef

McShane LM, Hayes DF (2012) Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol 30:4223–4232. doi:10.1200/JCO.2012.42.6858 PubMedPubMedCentralCrossRef

Melbo-Jorgensen C, Ness N et al (2014) Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6. PLoS One 9:e113039. doi:10.1371/journal.pone.0113039 PubMedPubMedCentralCrossRef

Mengual L, Lozano JJ et al (2013) Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer 133:2631–2641. doi:10.1002/ijc.28274 PubMed

Miah S, Dudziec E et al (2012) An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer 107:123–128. doi:10.1038/bjc.2012.221 PubMedPubMedCentralCrossRef

Mitchell PS, Parkin RK et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513–10518. doi:10.1073/pnas.0804549105 PubMedPubMedCentralCrossRef

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006–1012. doi:10.1016/j.jclinepi.2009.06.005 PubMedCrossRef

Moltzahn F, Olshen AB et al (2011) Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 71:550–560. doi:10.1158/0008-5472.CAN-10-1229 PubMedCrossRef

Nguyen HC, Xie W et al (2013) Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 73:346–354. doi:10.1002/pros.22572 PubMedCrossRef

Nordentoft I, Birkenkamp-Demtroder K et al (2012) miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genom 5:40. doi:10.1186/1755-8794-5-40 CrossRef

Ozen M, Creighton CJ, Ozdemir M, Ittmann M (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27:1788–1793. doi:10.1038/sj.onc.1210809 PubMedCrossRef

Patard JJ, Pignot G et al (2011) ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol 60:684–690. doi:10.1016/j.eururo.2011.06.017 PubMedCrossRef

Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM (2013) Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 18:282–289. doi:10.1016/j.drudis.2012.10.002 PubMedCrossRef

Petillo D, Kort EJ et al (2009) MicroRNA profiling of human kidney cancer subtypes. Int J Oncol 35:109–114PubMedCrossRef

Petrovich Z, Lieskovsky G, Stein JP, Huberman M, Skinner DG (2002) Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer. BJU Int 89:604–611PubMedCrossRef

Pignot G, Cizeron-Clairac G et al (2013) microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 132:2479–2491. doi:10.1002/ijc.27949 PubMedCrossRef

Porkka KP, Pfeiffer MJ et al (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67:6130–6135. doi:10.1158/0008-5472.CAN-07-0533 PubMedCrossRef

Prior C, Perez-Gracia JL et al (2014) Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One 9:e86263. doi:10.1371/journal.pone.0086263 PubMedPubMedCentralCrossRef

Puerta-Gil P, Garcia-Baquero R et al (2012) miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 180:1808–1815. doi:10.1016/j.ajpath.2012.01.034 PubMedCrossRef

Ransohoff DF (2004) Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4:309–314. doi:10.1038/nrc1322 PubMedCrossRef

Ratert N, Meyer HA et al (2013) miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn 15:695–705. doi:10.1016/j.jmoldx.2013.05.008 PubMedCrossRef

Redova M, Poprach A et al (2012) Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 10:55. doi:10.1186/1479-5876-10-55 PubMedPubMedCentralCrossRef

Rosenberg E, Baniel J et al (2013) Predicting progression of bladder urothelial carcinoma using microRNA expression. BJU Int 112:1027–1034. doi:10.1111/j.1464-410X.2012.11748.x PubMed

Samaan S, Khella HW et al (2015) miR-210 is a prognostic marker in clear cell renal cell carcinoma. J Mol Diagn 17:136–144. doi:10.1016/j.jmoldx.2014.10.005 PubMedCrossRef

Sapre N, Hong MK et al (2014) Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer. PLoS One 9:e91729. doi:10.1371/journal.pone.0091729 PubMedPubMedCentralCrossRef

Schaefer A, Jung M et al (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126:1166–1176. doi:10.1002/ijc.24827 PubMed

Scheffer AR, Holdenrieder S et al (2014) Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol 32:353–358. doi:10.1007/s00345-012-1010-2 PubMedCrossRef

Schubert M, Spahn M et al (2013) Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS One 8:e65064. doi:10.1371/journal.pone.0065064 PubMedPubMedCentralCrossRef

Segersten U, Spector Y, Goren Y, Tabak S, Malmstrom PU (2014) The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer. Urol Oncol 32:613–618. doi:10.1016/j.urolonc.2013.11.001 PubMedCrossRef

Selth LA, Townley S et al (2012) Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 131:652–661. doi:10.1002/ijc.26405 PubMedCrossRef

Selth LA, Townley SL et al (2013) Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 109:641–650. doi:10.1038/bjc.2013.369 PubMedPubMedCentralCrossRef

Shen J, Hruby GW et al (2012) Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72:1469–1477. doi:10.1002/pros.22499 PubMedPubMedCentralCrossRef

Shi GH, Ye DW et al (2010) Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin 31:867–873. doi:10.1038/aps.2010.48 PubMedPubMedCentralCrossRef

Silva-Santos RM, Costa-Pinheiro P et al (2013) MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. Br J Cancer 109:2646–2653. doi:10.1038/bjc.2013.552 PubMedPubMedCentralCrossRef

Singh PK, Preus L et al (2014) Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget 5:824–840PubMedPubMedCentralCrossRef

Slaby O, Redova M et al (2012) Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer 51:707–716. doi:10.1002/gcc.21957 PubMedCrossRef

Smith SC, Baras AS et al (2011) A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 12:137–143. doi:10.1016/S1470-2045(10)70296-5 PubMedPubMedCentralCrossRef

Spahn M, Joniau S et al (2010a) Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 58:1–7. doi:10.1016/j.eururo.2010.03.001 (discussion 10–11) PubMedCrossRef

Spahn M, Kneitz S et al (2010b) Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 127:394–403. doi:10.1002/ijc.24715 PubMed

Staehler M, Haseke N et al (2007) Modern therapeutic approaches in metastatic renal cell carcinoma. EAU-EBU Update Ser 5:26–37. doi:10.1016/j.eeus.2006.08.004 CrossRef

Sturgeon CM, Duffy MJ et al (2008) National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54:e11–e79. doi:10.1373/clinchem.2008.105601 PubMedCrossRef

Szczyrba J, Loprich E et al (2010) The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 8:529–538. doi:10.1158/1541-7786.MCR-09-0443 PubMedCrossRef

Tannock IF, de Wit R et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512. doi:10.1056/NEJMoa040720 PubMedCrossRef

Teixeira AL, Ferreira M et al (2014) Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol 35:4057–4066. doi:10.1007/s13277-013-1531-3 PubMedCrossRef

Tolle A, Jung M et al (2013) Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer. Oncol Rep 30:1949–1956. doi:10.3892/or.2013.2621 PubMed

Torre LA, Bray F et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. doi:10.3322/caac.21262 PubMedCrossRef

True L, Coleman I et al (2006) A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 103:10991–10996. doi:10.1073/pnas.0603678103 PubMedPubMedCentralCrossRef

Valadi H, Ekstrom K et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659. doi:10.1038/ncb1596 PubMedCrossRef

Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13:423–433. doi:10.1038/ncb2210 PubMedPubMedCentralCrossRef

Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW (2012) MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer 130:2526–2538. doi:10.1002/ijc.26256 PubMedCrossRef

von Brandenstein M, Pandarakalam JJ et al (2012) MicroRNA 15a, inversely correlated to PKCalpha, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol 180:1787–1797. doi:10.1016/j.ajpath.2012.01.014 CrossRef

Wach S, Nolte E et al (2012) MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 130:611–621. doi:10.1002/ijc.26064 PubMedCrossRef

Walter BA, Valera VA, Pinto PA, Merino MJ (2013) Comprehensive microRNA profiling of prostate cancer. J Cancer 4:350–357. doi:10.7150/jca.6394 PubMedPubMedCentralCrossRef

Wang L, Tang H et al (2009) Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 69:9490–9497. doi:10.1158/0008-5472.CAN-09-2183 PubMedPubMedCentralCrossRef

Wang G, Chan ES et al (2012a) Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer 10:106–113. doi:10.1016/j.clgc.2012.01.001 PubMedCrossRef

Wang S, Xue S et al (2012b) Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol 7:159. doi:10.1186/1746-1596-7-159 PubMedPubMedCentralCrossRef

Wang S, Li Q et al (2013) Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. Clin Transl Oncol 15:849–854. doi:10.1007/s12094-013-1014-4 PubMedCrossRef

Wang XL, Xie HY et al (2014) Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer. Tumour Biol 36:877–883. doi:10.1007/s13277-014-2656-8 PubMedCrossRef

Watahiki A, Macfarlane RJ et al (2013) Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. Int J Mol Sci 14:7757–7770. doi:10.3390/ijms14047757 PubMedPubMedCentralCrossRef

Weber JA, Baxter DH et al (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56:1733–1741. doi:10.1373/clinchem.2010.147405 PubMedPubMedCentralCrossRef

Wiklund ED, Bramsen JB et al (2011) Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 128:1327–1334. doi:10.1002/ijc.25461 PubMedCrossRef

Wilt TJ, Brawer MK et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213. doi:10.1056/NEJMoa1113162 PubMedPubMedCentralCrossRef

Wu X, Weng L et al (2012) Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 7:e35661. doi:10.1371/journal.pone.0035661 PubMedPubMedCentralCrossRef

Wulfken LM, Moritz R et al (2011) MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 6:e25787. doi:10.1371/journal.pone.0025787 PubMedPubMedCentralCrossRef

Yamada Y, Enokida H et al (2011) MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 102:522–529. doi:10.1111/j.1349-7006.2010.01816.x PubMedCrossRef

Yaman Agaoglu F, Kovancilar M et al (2011) Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 32:583–588. doi:10.1007/s13277-011-0154-9 PubMedCrossRef

Yossepowitch O, Eggener SE et al (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178:493–499 (discussion 499) PubMedCrossRef

Youssef YM, White NM et al (2011) Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 59:721–730. doi:10.1016/j.eururo.2011.01.004 PubMedCrossRef

Yun SJ, Jeong P et al (2012) Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol 41:1871–1878. doi:10.3892/ijo.2012.1622 PubMed

Zabolotneva AA, Zhavoronkov AA et al (2013) A systematic experimental evaluation of microRNA markers of human bladder cancer. Front Genet 4:247. doi:10.3389/fgene.2013.00247 PubMedPubMedCentralCrossRef

Zaman MS, Shahryari V et al (2012) Up-regulation of microRNA-21 correlates with lower kidney cancer survival. PLoS One 7:e31060. doi:10.1371/journal.pone.0031060 PubMedPubMedCentralCrossRef

Zen K, Zhang CY (2012) Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 32:326–348. doi:10.1002/med.20215 PubMedCrossRef

Zhai Q, Zhou L et al (2012) Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem Biophys Res Commun 419:621–626. doi:10.1016/j.bbrc.2012.02.060 PubMedCrossRef

Zhang HL, Yang LF et al (2011) Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71:326–331. doi:10.1002/pros.21246 PubMedCrossRef

Zhang DZ, Lau KM et al (2014) Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer. PLoS One 9:e100793. doi:10.1371/journal.pone.0100793 PubMedPubMedCentralCrossRef

Zhao A, Li G, Peoc’h M, Genin C, Gigante M (2013) Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 94:115–120. doi:10.1016/j.yexmp.2012.10.005 PubMedCrossRef

Zhao JJ, Chen PJ et al (2014) Up-regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival. Int J Clin Exp Pathol 7:3318–3323PubMedPubMedCentral

Title: Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?
Authors: Maria Schubert
Kerstin Junker
Joana Heinzelmann
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 8/2016
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-2089-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2016

High-risk and low-risk gastric cancer areas in Italy and its association with microsatellite instability

Altered CXCL12 expression reveals a dual role of CXCR4 in osteosarcoma primary tumor growth and metastasis

Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival

Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer

The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma

Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page